TD Cowen raised the firm’s price target on DexCom to $160 from $110 and keeps an Outperform rating on the shares. The firm said they remain bullish on the 2024 outlook for G7 and CGM use among basal insulin users. The company also will expand its addressable market with Stelo designed for type 2 patients who do not use insulin which should launch in the US this summer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXCM:
- DXCM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- DexCom price target raised to $140 from $137 at Canaccord
- DexCom breaks ground on new manufacturing facility in Ireland
- DexCom price target raised to $145 from $136 at Wells Fargo
- DexCom sees FY24 revenue $4.15B-$4.35B, consensus $4.32B
